James D Chambers

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. doi request reprint Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain
    James D Chambers
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, School of Medicine, Tufts University, Boston, Massachusetts, USA
    Health Aff (Millwood) 32:1109-15. 2013
  2. doi request reprint Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Value Health 16:629-38. 2013
  3. doi request reprint What can we learn from the U.S. expanded end-stage renal disease bundle?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Health Policy 110:164-71. 2013
  4. doi request reprint Factors predicting Medicare national coverage: an empirical analysis
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Care 50:249-56. 2012
  5. doi request reprint Does Medicare have an implicit cost-effectiveness threshold?
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Decis Making 30:E14-27. 2010
  6. doi request reprint Medicare's enduring struggle to define "reasonable and necessary" care
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA
    N Engl J Med 367:1775-7. 2012
  7. doi request reprint Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits
    Hansel Javier Otero
    Department of Radiology, Institute for Clinical Research and Health Policy Studies, Boston, MA 02111, USA
    Acad Radiol 19:1060-5. 2012
  8. doi request reprint Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 31:700-8. 2012
  9. doi request reprint Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
    Peter J Neumann
    Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Aff (Millwood) 30:2329-37. 2011

Detail Information

Publications9

  1. doi request reprint Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain
    James D Chambers
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, School of Medicine, Tufts University, Boston, Massachusetts, USA
    Health Aff (Millwood) 32:1109-15. 2013
    ..Our findings also provide important insights for the FDA's and Medicare's pilot parallel review program...
  2. doi request reprint Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Value Health 16:629-38. 2013
    ..The objective of this study was to illustrate potential efficiency gains from reallocating Medicare expenditures by using cost-effectiveness information, and the consequences for health gains among Medicare beneficiaries...
  3. doi request reprint What can we learn from the U.S. expanded end-stage renal disease bundle?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Health Policy 110:164-71. 2013
    ..Bundled payment policies offer opportunities and challenges. Their success will be determined not only by impacts on cost containment, but also to the extent they encourage high quality care...
  4. doi request reprint Factors predicting Medicare national coverage: an empirical analysis
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Care 50:249-56. 2012
    ..Medicare coverage for such interventions is limited to those deemed "reasonable and necessary" for the diagnosis or treatment of an illness or injury. What constitutes reasonable and necessary has not, however, been clearly defined...
  5. doi request reprint Does Medicare have an implicit cost-effectiveness threshold?
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Decis Making 30:E14-27. 2010
    ..Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) has maintained a policy that cost-effectiveness is not considered in national coverage determinations (NCDs)...
  6. doi request reprint Medicare's enduring struggle to define "reasonable and necessary" care
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA
    N Engl J Med 367:1775-7. 2012
    ..In today's fiscal environment, "reasonable and necessary" warrants a closer look...
  7. doi request reprint Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits
    Hansel Javier Otero
    Department of Radiology, Institute for Clinical Research and Health Policy Studies, Boston, MA 02111, USA
    Acad Radiol 19:1060-5. 2012
    ..To systematically review and summarize the Center for Medicare and Medicaid Services (CMS) national coverage determination (NCDs) pertaining diagnostic imaging technologies from 1999 through 2010...
  8. doi request reprint Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 31:700-8. 2012
    ..Worldwide, we demonstrate that health technology assessment organizations are struggling with cancer's "exceptionalism."..
  9. doi request reprint Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
    Peter J Neumann
    Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Aff (Millwood) 30:2329-37. 2011
    ..For the foreseeable future, they are likely to remain the exception as drug companies pursue payment models unconnected to data collection or performance assessment...